Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Guangyi Yang
Observed name:
Guang-Yi Yang
Institutions:
Guangzhou University of Chinese Medicine,
South China Normal University,
Northwest A&F University
Observed institutions:
Guangzhou University of Chinese Medicine,
Henan University of Science and Technology,
South China Normal University,
Anyang Tumor Hospital,
Huazhong University of Science and Technology,
Southeast University,
Northwest A&F University
show all 7
ORCID:
0009-0009-9832-1243
Observed ORCID:
0009-0009-9832-1243
OpenAlex ID:
A5065444744
Isoginkgetin, a potential CDK6 inhibitor, suppresses SLC2A1/GLUT1 enhancer activity to induce AMPK-ULK1-mediated cytotoxic autophagy in hepatocellular carcinoma
2022
·
Jie Yao
, Shuming Tang
, et al.
·
Autophagy
·
79
PDF
From farm to table: application and challenges of yeast in the growth, preservation and fermentation of fruit
2025
·
Xiaohua Ma
, Guangyi Yang
, et al.
·
Trends in Food Science & Technology
·
15
Does Climate Policy Uncertainty Affect Bank Systemic Risk?- Empirical Evidence from China
2024
·
Chenyao Zhang
, Xiaoxing Liu
, et al.
·
Emerging Markets Finance and Trade
·
11
Efficacy and Safety of Apatinib plus Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cancer: A Phase II Trial
2022
·
Bo Yang
, Xiaofeng Guo
, et al.
·
BioMed Research International
·
5
PDF
Research on the application of a high-throughput fully automated bacterial growth curve monitor for screening natural antibacterial compounds
2025
·
Shuangli Chen
, Chengshuo Deng
, et al.
·
BMC Microbiology
·
4
PDF
Spin–orbit torque true random number generator with thermal stability
2024
·
Cen Wang
, Tianyang Zhao
, et al.
·
Applied Physics Letters
·
3
Serotonergic Projection from the Dorsal Raphe Nucleus to the Basolateral Amygdala Bidirectionally Modulates Sociability in Mice
2025
·
Yehui Zhang
, Yuxiang Zhang
, et al.
·
Neuroscience Bulletin
·
2
Corporate Financing Liquidity and Financial Risk: A Dynamic Macro–Micro Mechanism Analysis
2025
·
Guangyi Yang
, Xiaoxing Liu
, et al.
·
SSRN Electronic Journal
Anlotinib combined with nab-paclitaxel and cisplatin as neoadjuvant treatment (NAT) for esophageal squamous cell carcinoma (ESCC): Update results of a single-arm, phase II clinical trial.
2023
·
Yan-Feng Zhang
, Xiao-Bing Li
, et al.
·
Journal of Clinical Oncology
Anlotinib combined with nab-paclitaxel and cisplatin as neoadjuvant treatment for esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.
2022
·
Yan-Feng Zhang
, An-Lin Hao
, et al.
·
Journal of Clinical Oncology
Show more works
View as search
Works count:
10
Citation count:
119
H-index:
4
I10-index:
3
Year
Topic
Type